enVVeno Medical Corp（NVNO）のニュースとイベント

$10.750

-0.469 (-4.36%)終値時点

NVNO のニュース

8.507-31Newsfilter

enVVeno Medical Secures FDA Approval, TAVVE Trial Set to Launch

8.507-07Newsfilter

enVVeno Secures New Patent for Core Technology

9.005-12Newsfilter

enVVeno Secures First FDA IDE Approval for Pivotal Study

9.004-29Newsfilter

enVVeno Medical Receives FDA Approval for TAVVE Trial

9.503-27seekingalpha

enVVeno Medical Reports FY GAAP EPS of -$33.06 Amid Reverse Stock Split

8.501-15seekingalpha

enVVeno Medical Approves 1-for-35 Reverse Stock Split, Reducing Shares to 655K

4.511-14Benzinga

Gold Drops More Than 2%; Cidara Therapeutics Stock Soars

4.511-14Benzinga

Nasdaq Falls by More Than 300 Points; Applied Materials Reports Positive Q4 Earnings

2.011-14Benzinga

RLX Technology Shares Rise 6%; Check Out 20 Stocks Making Moves in Premarket Trading

4.508-20Benzinga

Nasdaq Declines 1%; Lowe's Reports Positive Earnings

ニュースをもっと見る

NVNO のイベント

8/21 17:00

enVVeno Medical Files $100M Mixed Securities Shelf

enVVeno Medical files $100M mixed securities shelf

7/31 09:00

enVVeno Approved to Proceed with enVVe Pivotal Study

"The second quarter represented a defining milestone for enVVeno, as we got the approval to move forward with the pivotal study for enVVe, our non-surgical replacement venous valve. enVVe has the potential to completely change the treatment trajectory for the 3 million U.S. patients in the U.S. that suffer from severe, deep venous CVI and have no effective treatment options," commented Rob Berman, CEO. "As we enter the second half of 2026, our focus is squarely on executing the TAVVE pivotal study, getting our clinical sites up and running, and treating the first patients."

7/31 09:00

Company Reports Q2 Cash Burn of $3.4M

Cash burn for the second quarter was $3.4M, consistent with the Company's projected cash burn rate of approximately $3M to $4M per quarter. The Company anticipates that its cash burn rate will likely increase to between $4M and $5M per quarter in the second half of 2026 as the TAVVE study begins enrolling patients.

7/15 09:00

enVVeno Medical Secures U.S. Patent, CEO Highlights Market Potential

enVVeno Medical announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment. As part of the segment, Berman discussed the Company's recent news announcing the issuance of the first U.S. Patent covering the company's enVVe system, further expanding its intellectual property portfolio and laying the groundwork to dominate the large and untapped replacement venous valve market. "Receiving a foundational U.S. patent while simultaneously advancing the first FDA-approved pivotal trial for a non-surgical replacement venous valve are both important fundamental parts of our strategy to build shareholder value," said Robert Berman, Chief Executive Officer of enVVeno Medical. "In this discussion, we explain why we believe these milestones significantly strengthen our long-term competitive position, reinforce the barriers to entry around our technology, and position the Company to pursue what we believe is a substantial commercial opportunity."

7/7 09:00

enVVeno Medical Secures U.S. Patent No. 12,575,932

enVVeno Medical announced the issuance of U.S. Patent No. 12,575,932, further expanding its intellectual property portfolio supporting its enVVe transcatheter replacement venous valve system for the treatment of venous disease. The issued patent covers key components of the enVVe system, including the enVVe valve, valve support frame, crimping system, and delivery system, as well as methods for use in treating patients with deep venous insufficiency. The enVVe system is the transcatheter evolution of the clinically proven surgical device, designed to restore proper one-way blood flow in the deep veins of the leg.

イベントをもっと見る

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。